What changes
- Except for select high-medical-need products, a product’s medical or adult-use designation is determined at the retail sale, not when it is cultivated or manufactured. The memo says this takes effect January 1, 2027. GM-2026-09, Background
- A cannabis product is designated medical cannabis once it is sold to a registered patient or caregiver. GM-2026-09, What changes
- A regulated product sold to a registered patient or registered caregiver must have both a patient-specific label and the medical cannabis symbol. If the symbol is not already on the label, the retailer applies it at the sale, along with the patient-specific label. GM-2026-09, Medical cannabis retail endorsement, labeling
- A business with a medical cannabis retail endorsement must give enrolled patients and caregivers priority service and keep patient consultations available. Microbusinesses, mezzobusinesses, and retailers must carry every high-medical-need product OCM identified and make it available within 24 hours of a request. A macrobusiness must have those products in stock and available for sale. GM-2026-09, Medical cannabis retail endorsement, requirements
- Effective January 1, 2027, medical cannabinoid products may no longer be formulated with artificially derived cannabinoids. A compliant product manufactured before that date may still be sold if it has not reached its expiration date. GM-2026-09, Medical cannabinoid product formulation
- The rule limit of 80 percent THC on adult-use vaporized concentrates does not apply to medical cannabinoid vape products sold to registered patients. The retailer is responsible for not selling a patient-restricted product to an adult-use customer. GM-2026-09, Medical cannabinoid product distinctions for retailers
